Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Genomic Analysis of Serial Chronic Lymphocytic Leukemia Samples Suggests That Epigenetic Changes, Rather Than Clonal Evolution, May Drive the Progression of This Leukemia

Emanuela M. Ghia, PhD, Erin Smith, PhD, Christopher DeBoever, Laura Z. Rassenti, Ph.D., Sophie Rozenzhak, Peter Shepard, PhD, Hakan Alakus, M.D., Olivier Harismendy, PhD, Christian L Barrett, Ph.D., Kelly A Frazer, Ph.D., Thomas J. Kipps, MD, PhD

Blood (2012) 120 (21): 4563.

https://doi.org/10.1182/blood.V120.21.4563.4563

Published: 2012

Journal Articles

The Target Genes and Prognostic Significance of Mir-150 in Chronic Lymphocytic Leukemia

Marek Mraz, MD, PhD, Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Liguang Chen, MD, PhD, Jessie-Farah Fecteau, Ph.D., Sarka Pospisilova, Dr, PhD, Hongying Li, PhD, Karen Messer, PhD, Thomas J. Kipps, MD, PhD

Blood (2012) 120 (21): 3859.

https://doi.org/10.1182/blood.V120.21.3859.3859

Published: 2012

Journal Articles

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Rainer Claus, MD, Amy S. Ruppert, MAS, David M. Lucas, PhD, Manuela Zucknick, PhD, Laura Z. Rassenti, Ph.D., Andrew Greaves, Donna S. Neuberg, ScD, William G. Wierda, MD, Ph.D., Michael J. Keating, MD, Jennifer R. Brown, MD, PhD, John G Gribben, Kanti R. Rai, M.D., Michael R. Grever, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, Christoph Plass, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 3865.

https://doi.org/10.1182/blood.V120.21.3865.3865

Published: 2012

Journal Articles

Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation

Suping Zhang, PhD, Liguang Chen, MD, PhD, Ling Zhang, Jian Yu, PhD, Laura Z. Rassenti, Ph.D., Thomas J. Kipps, MD, PhD

Blood (2012) 120 (21): 3872.

https://doi.org/10.1182/blood.V120.21.3872.3872

Published: 2012

Journal Articles

Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia

Catherine C Coombs, MD, Laura Z. Rassenti, Ph.D., Susan L Slager, PhD, Sara Strom, PhD, J. Brice Weinberg, MD, Thomas J Kipps, MD, PhD, Mark C Lanasa, MD, PhD

Blood (2011) 118 (21): 1785.

https://doi.org/10.1182/blood.V118.21.1785.1785

Published: 2011

Journal Articles

A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo

Suping Zhang, PhD, Christina C.N. Wu, Ph.D., Jessie-Farah Fecteau, Ph.D., Bing Cui, PhD, Rongrong Wu, Laura Z. Rassenti, Ph.D., Fitzgerald S. Lao, B.S., Rommel Tawatao, B.S., Stefan Weigland, PhD, Charles Prussak, PhD, Dennis A. Carson, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 927.

https://doi.org/10.1182/blood.V118.21.927.927

Published: 2011

Journal Articles

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Danelle F. James, M.D., Jennifer R. Brown, MD, PhD, Lillian Werner, William G. Wierda, MD, PhD, Jaqueline C. Barrientos, MD, Januario Castro, MD, Andrew Greaves, Laura Z. Rassenti, Ph.D., Kanti R. Rai, MD, Donna Neuberg, ScD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 291.

https://doi.org/10.1182/blood.V118.21.291.291

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Matthew Kaufman, MD, Xiao J. Yan, MD, PhD, Emanuela M. Ghia, PhD, Donna Neuberg, ScD, Laura Z. Rassenti, Ph.D., Kostas Stamatopoulos, MD, Paolo Ghia, MD, PhD, David G Oscier, MD, Frederic Davi, MD, PhD, Richard Rosenquist, MD, PhD, Chrysoula Belessi, MD, Zadie Davis, PhD, Andreas Agathangelidis, Neil Kay, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Kanti R. Rai, M.D., Thomas J. Kipps, M.D., Ph.D, Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 288.

https://doi.org/10.1182/blood.V118.21.288.288

Published: 2011

Journal Articles

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, Muller Fabbri, MD, Stefano Volinia, PhD, George F. Widhopf, II, PhD, Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2846.

https://doi.org/10.1182/blood.V118.21.2846.2846

Published: 2011

Journal Articles

Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia,

Raymond P. Wu, Ph.D., Christina C.N. Wu, Ph.D., Tomoko Hayashi, M.D., Ph.D., Laura Z. Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D, Dennis A. Carson, M.D.

Blood (2011) 118 (21): 3867.

https://doi.org/10.1182/blood.V118.21.3867.3867

Published: 2011

Journal Articles

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Emanuela M. Ghia, PhD, Lillian Werner, Danelle F. James, M.D., Donna Neuberg, ScD, Laura G Corral, Senior, Scientist, Laura Z. Rassenti, Ph.D., Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3885.

https://doi.org/10.1182/blood.V118.21.3885.3885

Published: 2011

Journal Articles

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, George F. Widhopf, II, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 3891.

https://doi.org/10.1182/blood.V118.21.3891.3891

Published: 2011

Journal Articles

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,

Han-Yu Chuang, Laura Z. Rassenti, Ph.D., Michelle Salcedo, BS, Kate Licon, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Robin Foa, Trey Ideker, PhD, Thomas Kipps

Blood (2011) 118 (21): 3564.

https://doi.org/10.1182/blood.V118.21.3564.3564

Published: 2011

Journal Articles

Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings

H. Elizabeth Broome, MD, Laura Z. Rassenti, Ph.D., Michael Y. Choi, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 4588.

https://doi.org/10.1182/blood.V118.21.4588.4588

Published: 2011

Journal Articles

Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors.

Michael J. Keating, M.B., B.S., Susan Lerner, Xuemei Wang, Laura Z. Rassenti, Ph.D., Susan O’Brien, M.D., Thomas J. Kipps, M.D., Ph.D., William G. Wierda, M.D., Ph.D

Blood (2008) 112 (11): 2093.

https://doi.org/10.1182/blood.V112.11.2093.2093

Published: 2008

Journal Articles

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Emanuela M. Ghia, PhD, Laura Z. Rassenti, Ph.D., George F. Widhopf, Ph.D., Donna S. Neuberg, Ph.D., Michael J. Keating, M.D., William G. Wierda, M.D., Ph.D., John G. Gribben, M.D., Jennifer R. Brown, M.D., Ph.D., Ian W. Flinn, M.D., Ph.D., Kanti R. Rai, M.D., John C. Byrd, M.D., Neil E. Kay, M.D., Andrew W. Greaves, B.S., Thomas J. Kipps, M.D.,Ph.D.

Blood (2006) 108 (11): 2774.

https://doi.org/10.1182/blood.V108.11.2774.2774

Published: 2006

NARROW

Genomic Analysis of Serial Chronic Lymphocytic Leukemia Samples Suggests That Epigenetic Changes, Rather Than Clonal Evolution, May Drive the Progression of This Leukemia

The Target Genes and Prognostic Significance of Mir-150 in Chronic Lymphocytic Leukemia

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation

Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia

A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia,

Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,

Relative Prognostic Significance of ZAP-70 and IGHV1-69 Expression in Chronic Lymphocytic Leukemia,

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,

Low Expression of ROR1 on Chronic Lymphocytic Leukemia Is Associated with Other Atypical Findings

Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors.

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only